A recent Canadian study has found that a drug prescribed to treat heart failure could protect kidney and heart health in individuals with type 2 diabetes and chronic kidney disease. Results from the study were presented on November 4, at ASN Kidney Week 2023 organized by the American Society of Nephrology, in Philadelphia. The study of a drug named “Sotagliflozin”, which has been approved by the FDA in May as a heart failure treatment, also involved non-diabetic patients.
Sotagliflozin, a dual SGLT 1 and 2 inhibitor, appears as effective in reducing kidney outcomes as other SGLT2 inhibitors. An analysis of data from the SCORED trial supports that sotagliflozin can lower the risk for chronic kidney disease (CKD) progression.
Sotagliflozin, a dual SGLT 1 and 2 inhibitor, appears as effective in reducing kidney outcomes as other SGLT2 inhibitors. An analysis of data from the SCORED trial supports that sotagliflozin can lower the risk for chronic kidney disease (CKD) progression.